Engineering antibody therapeutics

被引:116
作者
Chiu, Mark L. [1 ]
Gilliland, Gary L. [1 ]
机构
[1] Janssen Res & Dev LLC, 1400 McKean Rd, Spring House, PA 19477 USA
关键词
PHYSICAL STABILITY PROFILES; HUMAN MONOCLONAL-ANTIBODIES; BISPECIFIC IGG ANTIBODIES; HIGH-AFFINITY ANTIBODIES; NEONATAL FC-RECEPTOR; ANTIGEN-BINDING SITE; SERUM HALF-LIFE; GLYCOFORM SELECTION; BIOLOGICAL-ACTIVITY; VARIABLE DOMAIN;
D O I
10.1016/j.sbi.2016.07.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The successful introduction of antibody-based protein therapeutics into the arsenal of treatments for patients has within a few decades fostered intense innovation in the production and engineering of antibodies. Reviewed here are the methods currently used to produce antibodies along with how our knowledge of the structural and functional characterization of immunoglobulins has resulted in the engineering of antibodies to produce protein therapeutics with unique properties, both biological and biophysical, that are leading to novel therapeutic approaches. Antibody engineering includes the introduction of the antibody combining site (variable regions) into a host of architectures including bi and multi-specific formats that further impact the therapeutic properties leading to further advantages and successes in patient treatment.
引用
收藏
页码:163 / 173
页数:11
相关论文
共 99 条
[1]   Synthetic antibody technologies [J].
Adams, Jarrett J. ;
Sidhu, Sachdev S. .
CURRENT OPINION IN STRUCTURAL BIOLOGY, 2014, 24 :1-9
[2]   PyIgClassify: a database of antibody CDR structural classifications [J].
Adolf-Bryfogle, Jared ;
Xu, Qifang ;
North, Benjamin ;
Lehmann, Andreas ;
Dunbrack, Roland L., Jr. .
NUCLEIC ACIDS RESEARCH, 2015, 43 (D1) :D432-D438
[3]   Aggregation in Protein-Based Biotherapeutics: Computational Studies and Tools to Identify Aggregation-Prone Regions [J].
Agrawal, Neeraj J. ;
Kumar, Sandeep ;
Wang, Xiaoling ;
Helk, Bernhard ;
Singh, Satish K. ;
Trout, Bernhardt L. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (12) :5081-5095
[4]   Protein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profiles [J].
Alsenaidy, Mohammad A. ;
Jain, Nishant K. ;
Kim, Jae H. ;
Middaugh, Russell ;
Volkin, David B. .
FRONTIERS IN PHARMACOLOGY, 2014, 5
[5]   Influence of immunoglobulin isotype on therapeutic antibody function [J].
Beers, Stephen A. ;
Glennie, Martin J. ;
White, Ann L. .
BLOOD, 2016, 127 (09) :1097-1101
[6]   Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab [J].
Benson, Jacqueline M. ;
Sachs, Clifford W. ;
Treacy, George ;
Zhou, Honghui ;
Pendley, Charles E. ;
Brodmerkel, Carrie M. ;
Shankar, Gopi ;
Mascelli, Mary A. .
NATURE BIOTECHNOLOGY, 2011, 29 (07) :615-624
[7]   Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site [J].
Bostrom, Jenny ;
Yu, Shang-Fan ;
Kan, David ;
Appleton, Brent A. ;
Lee, Chingwei V. ;
Billeci, Karen ;
Man, Wenyan ;
Peale, Franklin ;
Ross, Sarajane ;
Wiesmann, Christian ;
Fuh, Germaine .
SCIENCE, 2009, 323 (5921) :1610-1614
[8]   Fcγ receptor pathways during active and passive immunization [J].
Bournazos, Stylianos ;
Ravetch, Jeffrey V. .
IMMUNOLOGICAL REVIEWS, 2015, 268 (01) :88-103
[9]   Human Antibody Production in Transgenic Animals [J].
Brueggemann, Marianne ;
Osborn, Michael J. ;
Ma, Biao ;
Hayre, Jasvinder ;
Avis, Suzanne ;
Lundstrom, Brian ;
Buelow, Roland .
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2015, 63 (02) :101-108
[10]   Taking immunogenicity assessment of therapeutic proteins to the next level [J].
Buettel, I. C. ;
Chamberlain, P. ;
Chowers, Y. ;
Ehmann, F. ;
Greinacher, A. ;
Jefferis, R. ;
Kramer, D. ;
Kropshofer, H. ;
Lloyd, P. ;
Lubiniecki, A. ;
Krause, R. ;
Mire-Sluis, A. ;
Platts-Mills, T. ;
Ragheb, J. A. ;
Reipert, B. M. ;
Schellekens, H. ;
Seitz, R. ;
Stas, P. ;
Subramanyam, M. ;
Thorpe, R. ;
Trouvin, J. -H. ;
Weise, M. ;
Windisch, J. ;
Schneider, C. K. .
BIOLOGICALS, 2011, 39 (02) :100-109